The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in <i>APOE</i> ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease.

Alzheimers Dement (N Y) · 2024 · PMC11694516 · PMID 39748842

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

As shown in Figure 2 , treatment with AGB101 in APOE ε4 non‐carriers with MCI due to AD significantly reduced atrophy of the left ERC and showed a trend toward significantly reduced atrophy in the right BA35 compared to placebo.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in &lt;i&gt;APOE&lt;/i&gt; ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease.

The sentences

The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in <i>APOE</i> ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease.